Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Maika Onishi"'
Autor:
Christine Chin, MD, Sitara Hirji, BA, Maika Onishi, MD, Richard Ha, MD, Bret Taback, MD, David P. Horowitz, MD, Eileen P. Connolly, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 4, Iss 2, Pp 253-260 (2019)
Purpose: Intraoperative radiation therapy (IORT) as a form of accelerated partial breast irradiation (APBI) is controversial given the limited evidence to support its efficacy. However, it remains an attractive option for low-risk patients with ducta
Externí odkaz:
https://doaj.org/article/0ea187f41d7245718362990c7f9cb8a9
Autor:
Sae Ishimaru, Gwenaëlle Gueguen, Seth E. Karol, Francisco J. Bautista Sirvent, Valeria Ceolin, Bianca F. Goemans, Marlous Bakker, Laura Di Laurenzio, Jennifer Lukin, Harm Van Tinteren, Gauri B. Sunkersett, Maika Onishi, Kristina Unnebrink, Dirk Reinhardt, Gwen L Nichols, E. Anders Kolb, C. Michel Zwaan
Publikováno v:
Blood. 140:3369-3370
Autor:
Pankit Vachhani, Evelyn M Flahavan, Tao Xu, Esprit Ma, Melissa Montez, Anda Gershon, Maika Onishi, Huan Jin, Grace Ku, Brannon Flores, Cat N Bui, Jonathan A Abbas, William Donnellan
Publikováno v:
The oncologist. 27(11)
Background Treatment with venetoclax + hypomethylating agents (HMAs) is standard-of-care for newly diagnosed (ND) patients with acute myeloid leukemia (AML) aged ≥75 years, or with comorbidities precluding intensive chemotherapy. We describe real-w
Autor:
Katherine D. Crew, Maika Onishi, Matthew Maurer, Kevin Kalinsky, Donna Buono, Elizabeth Shane, Dawn L. Hershman, Madeleine B Hopson, Danielle Awad
Publikováno v:
Clinical Breast Cancer. 20:e327-e333
Ovarian suppression from chemotherapy results in bone loss in premenopausal women with breast cancer (BC). Less is known about bone microarchitecture changes. We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to measure vo
Autor:
Erin Honan, Melissa K. Accordino, Ruby Wu, Kathleen Fenn, Tizita Z. Zeleke, Kevin Kalinsky, Cody Chiuzan, Qingfei Pan, Dawn L. Hershman, Jose Silva, Jiyang Yu, Matthew Maurer, Meghna S. Trivedi, Katherin D Crew, Maika Onishi, Sean A. Kelly
Publikováno v:
Cancer Research. 80:P1-19
Background:HDAC6, a cytoplasmic histone deacetylase, impacts cell viability by influencing protein metabolism, microtubule dynamics, and chaperone function. ACY-1215 is an orally active, selective HDAC6 inhibitor. Preclinical studies have demonstrate
Autor:
Fredrik Schjesvold, Bruno Paiva, Vincent Ribrag, Paula Rodriguez-Otero, Jesus F. San-Miguel, Pawel Robak, Markus Hansson, Maika Onishi, Habib Hamidi, Vikram Malhi, Monique Dail, Apurva Javery, Grace Ku, Marc S. Raab
Introduction Mitogen-activated protein kinase pathway mutations are present in >50% of patients with relapsed/refractory (R/R) multiple myeloma (MM). MEK inhibitors show limited single-agent activity in R/R MM; combination with B-cell lymphoma-2 (BCL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85ea0d26ae2a8ae76a89feaa98cb64f4
http://hdl.handle.net/10852/99552
http://hdl.handle.net/10852/99552
Autor:
Richard Ha, Sitara H. Hirji, David P. Horowitz, Maika Onishi, Eileen P. Connolly, Christine Chin, Bret Taback
Publikováno v:
Advances in Radiation Oncology
Advances in Radiation Oncology, Vol 4, Iss 2, Pp 253-260 (2019)
Advances in Radiation Oncology, Vol 4, Iss 2, Pp 253-260 (2019)
Purpose Intraoperative radiation therapy (IORT) as a form of accelerated partial breast irradiation (APBI) is controversial given the limited evidence to support its efficacy. However, it remains an attractive option for low-risk patients with ductal
Autor:
Tizita Z. Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J. Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S. Trivedi, Melissa Accordino, Katherine D. Crew, Dawn L. Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin Kalinsky, Jiyang Yu, Jose Silva
Publikováno v:
Nature cancer.
Inhibiting individual histone deacetylase (HDAC) is emerging as well-tolerated anticancer strategy compared with pan-HDAC inhibitors. Through preclinical studies, we demonstrated that the sensitivity to the leading HDAC6 inhibitor (HDAC6i) ricolinsta
Autor:
David J. Hellerstein, Mark Olfson, Maika Onishi, John C. Markowitz, Cindy Varona, Ying Chen, Carlos Blanco, Melanie M. Wall, Mayumi Okuda, Jon A. Levenson, Dawn L. Hershman, Arthur M. Nezu
Publikováno v:
Breast Cancer Research and Treatment. 173:353-364
PURPOSE: Breast cancer (BC) is a risk factor for major depressive disorder (MDD), yet little research has tested the efficacy of different psychotherapies for depressed women with BC. This study, the largest to date, compared outcomes of three eviden
Autor:
Esprit Ma, Maika Onishi, Huan Jin, Pankit Vachhani, Evelyn M. Flahavan, Brannon Flores, Cat N. Bui, Anda Gershon, Grace Ku, Weize Huang, Jonathan A. Abbas, William B. Donnellan, Melissa Montez, Tao Xu
Publikováno v:
Blood. 138:2290-2290
Background: Ven+HMA is now a standard treatment (Tx) for newly diagnosed (ND) AML in patients (pts) aged ≥75 years (y), or with comorbidities precluding intensive chemotherapy. The Phase 3 VIALE-A trial demonstrated clinical benefit and longer over